Analysts upgrade KalVista Pharmaceuticals to "strong-buy" and "buy" ratings, despite Q2 miss.
Cantor Fitzgerald upgraded KalVista Pharmaceuticals to a "strong-buy" rating and HC Wainwright reaffirmed a "buy" with a $20 price target. The clinical-stage pharmaceutical company, with a focus on small molecule protease inhibitors for HAE and DME, saw insiders sell shares and institutional investors increase their holdings. Despite a Q2 earnings miss, KalVista has received support from analysts and investors.
August 27, 2024
127 Articles